Cancer Family
Neck Neoplasm
CI-CAN-00000283Explore in graph →
Non-malignant634 active trials11 approved drugs67 evidence items
- NCIt
- C3260
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000283Explore in graph →
Clinical trials
2,377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | terminated | Phase 1 | 154 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 115 | SOTIO Biotech AGINDUSTRY | 4 | Mar 27, 2026 |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors | terminated | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05721222 | Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001) | terminated | Phase 1 / Phase 2 | 42 | GenmabINDUSTRY | 2 | Mar 4, 2026 | clinicaltrials |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 61 | TakedaINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03144661 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | terminated | Phase 1 | 25 | Incyte CorporationINDUSTRY | 2 | Oct 21, 2025 | clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT06270082 | Study of IK-595 in RAS- or RAF-altered Advanced Tumors | terminated | Phase 1 | 75 | Ikena OncologyINDUSTRY | 1 | Sep 19, 2025 | clinicaltrials |
| NCT03469011 | A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer. | terminated | Phase 1 | 14 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 87 | HutchmedINDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | terminated | Phase 1 | 27 | Turnstone Biologics, Corp.INDUSTRY | 3 | Apr 23, 2025 | clinicaltrials |
| NCT05166577 | Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC | terminated | Phase 1 | 26 | Viracta Therapeutics, Inc.INDUSTRY | 8 | Mar 12, 2025 | clinicaltrials |
| NCT04588038 | NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery | terminated | Phase 1 | 4 | Hyunseok Kang, MDOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | terminated | Phase 1 / Phase 2 | 15 | Aminex Therapeutics, Inc.INDUSTRY | 2 | Dec 24, 2024 | clinicaltrials |
| NCT03769467 | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | terminated | Phase 1 / Phase 2 | 12 | Atara BiotherapeuticsINDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer(PDL1x41BB) | terminated | Phase 1 | 160 | Inhibrx Biosciences, IncINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | terminated | Phase 1 / Phase 2 | 3 | NantCell, Inc.INDUSTRY | 1 | Aug 6, 2024 | clinicaltrials |
| NCT04161391 | Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations | terminated | Phase 1 / Phase 2 | 41 | Turning Point Therapeutics, Inc.INDUSTRY | 2 | Jun 13, 2024 | clinicaltrials |
| NCT03618134 | Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner | terminated | Phase 1 / Phase 2 | 19 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT03682055 | Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) | terminated | Phase 1 / Phase 2 | 14 | Cullinan Therapeutics Inc.INDUSTRY | 5 | Aug 15, 2023 | clinicaltrials |
| NCT02698111 | Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma | terminated | Phase 1 / Phase 2 | 20 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | May 8, 2023 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT03131206 | A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. | terminated | Phase 1 | 5 | Fore BiotherapeuticsINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 200 | AbbVieINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00603941 | A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel | terminated | Phase 1 / Phase 2 | 19 | Daiichi SankyoINDUSTRY | 1 | Sep 16, 2020 | clinicaltrials |
| NCT02464137 | HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer(HYDRA) | terminated | Phase 1 | 15 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | terminated | Phase 1 | 17 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 29, 2020 | clinicaltrials |
| NCT02569788 | Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma | terminated | Phase 1 / Phase 2 | 9 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02801487 | Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma | terminated | Phase 1 / Phase 2 | 6 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT00923247 | A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) | terminated | Phase 1 / Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2018 | clinicaltrials |
| NCT01283178 | Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC | terminated | Phase 1 | 3 | Virginia Commonwealth UniversityOTHER | 1 | Oct 31, 2016 | clinicaltrials |
| NCT01528137 | Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer | terminated | Phase 1 | 4 | Stanford UniversityOTHER | 1 | Aug 2, 2016 | clinicaltrials |
| NCT02334319 | Ganetespib Window of Opportunity Study in Head and Neck Cancers | terminated | Phase 1 | 3 | Emory UniversityOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT02058017 | OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy | terminated | Phase 1 | 9 | National University Hospital, SingaporeOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT00354523 | Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma | terminated | Phase 1 / Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 17, 2014 | clinicaltrials |
| NCT00906360 | Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00033449 | Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00081211 | Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00080028 | Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer | terminated | Phase 1 | 18 | Pharmacyclics LLC.INDUSTRY | 1 | May 8, 2007 | clinicaltrials |
Data updated 22 days agoSource updated May 15, 2026source: clinicaltrials